Precision Weight Loss
Tirzepatide (injection)
A once-weekly injection that works on two gut hormone pathways rather than one.
Browse freely. To purchase medication, you’ll enroll in membership and complete a clinician review. Medication is charged separately and is prescribed only when clinically appropriate.
Availability & pricing
Availability and pricing depend on your state.
Not available to purchase yet
Choose your state to see current availability and pricing.
Check another state or optionMeet Tirzepatide (injection)
How it works
A dual agonist: it activates both the GIP and the GLP-1 receptor, where semaglutide acts on GLP-1 alone. Both are gut hormones released after eating. Whether acting on two pathways rather than one matters for a given person is a clinical question, not a marketing one.
What to expect
Gradual weight change beginning during titration. Nausea, fullness and constipation are common early and usually settle as the dose stabilises. Head-to-head trial data suggests greater average weight reduction than semaglutide, at a higher price and with the same class side effects.
From your clinician’s notes
Tirzepatide acts on two receptors — GIP and GLP-1 — where semaglutide acts on one. Whether that difference matters for you is a clinical question, not a marketing one, and it is exactly the sort of thing to raise in your intake and with your coach. It is given as a small injection just under the skin, once a week, into the abdomen, thigh, or upper arm. Your dose starts low and steps up over time, on a schedule your clinician sets from your intake, your labs, and how you respond. Included with your $149 monthly membership: your starter lab panel, one-on-one health coaching, 24/7 clinician access, and the member portal where your dose, refills, and shipments live. Billed separately: the medication, monthly, plus shipping. Tirzepatide costs more than semaglutide, and that difference is visible in the price rather than folded into a tier. You are not charged for medication until a clinician has approved it and the pharmacy has accepted the order. Compounded by a licensed 503A pharmacy, not a manufactured brand-name product, and the two are not interchangeable. Prescription required. Completing an application does not mean tirzepatide will be prescribed.
Uses and regulatory status
Chronic weight management alongside a change in diet and physical activity, in adults who meet the clinical criteria.
Tirzepatide is FDA-approved for chronic weight management. The preparation dispensed here is compounded by a licensed 503A pharmacy and is NOT an FDA-approved finished product; compounded preparations are not reviewed by the FDA for safety, effectiveness or manufacturing quality.
Chronic weight management is an FDA-approved indication for this active ingredient. The indication is approved; this compounded formulation is not itself an approved product.
Safety & monitoring
Important safety information
Contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, and in pregnancy. Uncommon but serious risks include pancreatitis and gallbladder disease. The same lean-mass caution applies as to any rapid weight loss.
Monitoring
Weight and waist at each check-in, blood pressure, and metabolic labs including HbA1c and lipids. Lean mass is tracked deliberately. Severe or persistent abdominal pain is reported the same day.
About this form
Administration, storage, evidence limits, formulation
- Administration
- One subcutaneous injection a week, on the same day each week, into the abdomen, thigh or upper arm, rotating sites. Draw the volume your clinician specifies — at 10 mg/mL a 10 mg dose is 1.0 mL. New needle every time, into a sharps container. If you miss a dose and the next is more than two days away, take it when you remember; otherwise skip it and never double up.
- Storage
- Refrigerate at 2-8 degrees C. Do not freeze, and discard rather than thaw anything that has. Keep the vial in its carton away from light and observe the pharmacy's beyond-use date once punctured.
- Evidence limits
- SURMOUNT and the head-to-head work studied the FDA-approved product. This is a compounded preparation with added glycine and cyanocobalamin that no trial has tested. Its behaviour is inferred from the approved product, not demonstrated for this formulation.
- Formulation
- Prepared by a licensed 503A compounding pharmacy (Strive) with added ingredients; not the FDA-approved finished product.
Compounded by a licensed 503A pharmacy. This is NOT an FDA-approved finished product: compounded preparations are not reviewed by the FDA for safety, effectiveness or manufacturing quality, and it is not interchangeable with the brand-name product. It also contains added ingredients not present in the approved formulation.
Medication guide
Discovery and background
GIP was the first incretin hormone identified, in the early 1970s, but on its own it looked disappointing for diabetes and was largely set aside for decades. The insight behind tirzepatide was that GIP and GLP-1 together behave differently from either alone. A single molecule engineered to hit both receptors turned out to outperform GLP-1 agonism by itself — reviving a hormone the field had written off.
Evidence
SURMOUNT-1 (NEJM 2022) randomised 2,539 adults with obesity or overweight without diabetes and reported dose-dependent weight reduction substantially greater than placebo over 72 weeks. Later head-to-head work against semaglutide favoured tirzepatide on average weight change. IMPORTANT LIMIT: those trials studied the FDA-approved product, not a compounded preparation. No trial has tested what is dispensed here.
Risks
Gastrointestinal effects are common and dose-related, and are the usual reason for stopping. Pancreatitis and gallbladder disease are uncommon but serious. Hypoglycaemia risk rises sharply in combination with insulin or a sulfonylurea. Lean mass loss and post-discontinuation weight regain apply here exactly as they do to semaglutide.
Interactions
Delayed gastric emptying can alter absorption of other oral medicines. Doses of insulin or sulfonylureas usually need reducing. Oral contraceptive absorption can be affected around dose escalation — if that applies to you, ask specifically, because it is easy to miss.
Frequently asked questions
Is tirzepatide better than semaglutide?
On average, trials show greater weight reduction with tirzepatide. Average is not you: side effect tolerance, cost, and what your labs show all matter, and some people do better on semaglutide. This is a conversation with your clinician rather than a ranking.
Why does it cost more?
The drug itself costs us more, and we price it separately rather than folding both into one tier. You can see the difference, which is the point.
What happens if I stop?
Weight regain after discontinuation is common and well documented. Your plan should say what happens when you stop, from the beginning.
Does the dual mechanism cause different side effects?
The side effect profile is broadly the class profile — mostly gastrointestinal, mostly early, mostly settling. There is no evidence that acting on GIP as well makes it meaningfully worse tolerated.
References
- FDA — Compounding and the FDA: Questions and Answers — published Feb 1, 2023; accessed Sep 2, 2026
- ZEPBOUND (tirzepatide) injection — FDA prescribing information — published Nov 8, 2023; accessed Sep 2, 2026
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205-216 — published Jul 21, 2022; accessed Sep 2, 2026
- FDA — Compounding and the FDA: Questions and Answers — published Feb 1, 2023; accessed Sep 2, 2026
- FDA — Safely Using Sharps (Needles and Syringes) at Home, at Work and on Travel — published Sep 1, 2021; accessed Sep 2, 2026
Ready when you are.
Check another state or optionBrowse freely. To purchase medication, you’ll enroll in membership and complete a clinician review. Medication is charged separately and is prescribed only when clinically appropriate.
Compounded by a licensed 503A pharmacy. This is NOT an FDA-approved finished product: compounded preparations are not reviewed by the FDA for safety, effectiveness or manufacturing quality, and it is not interchangeable with the brand-name product. It also contains added ingredients not present in the approved formulation.
Chronic weight management is an FDA-approved indication for this active ingredient. The indication is approved; this compounded formulation is not itself an approved product.